Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - Raymond James raised its price target on Disc Medicine (NASDAQ:IRON) to $108.00 from $89.00 while maintaining a Strong Buy rating. The stock, currently trading at $74.36 with a market cap of $2.59 billion, has shown impressive momentum with a 76% gain over the past six months.
The price target increase follows Disc Medicine’s announcement that its drug bitopertin was selected for the FDA Commissioner’s National Priority Voucher (CNPV) program.
Raymond James views this development as "highly positive," noting it could accelerate bitopertin’s launch for erythropoietic protoporphyria (EPP) by more than a quarter.
The investment firm expressed increased confidence in the prospects for accelerated approval of bitopertin, which it believes can generate "substantial commercial value" in EPP and X-linked protoporphyria (XLP) markets even with modest market penetration.
Raymond James also noted that Disc Medicine’s additional pipeline programs represent "interesting opportunities" that are currently undervalued by investors.
In other recent news, Disc Medicine has made significant strides with its investigational drug bitopertin, receiving a Commissioner’s National Priority Voucher (CNPV) from the U.S. Food and Drug Administration. This voucher is part of a program aimed at expediting the review process for drugs addressing national health priorities. Disc Medicine submitted a New Drug Application for bitopertin in September 2025, targeting erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in patients aged 12 and older. The drug has already been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA.
Following these developments, Leerink Partners raised its price target for Disc Medicine to $100 from $85, maintaining an Outperform rating on the stock. In corporate governance news, Mona Ashiya, a Class I member of Disc Medicine’s board of directors, resigned, reducing the board size from nine to eight members. Her resignation was not due to any disagreement with the company’s operations or policies. These recent advancements and changes in leadership have positioned Disc Medicine for potential growth and development in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.